Close Many team members at Unicorn Nest are Ukrainians affected by Russian aggression. We do our best to solve any issues and answer your questions in the shortest possible time frames but some delays are possible.

6 Dimensions Capital

Investor type Venture Capital


Unlock datapoints

Portfolio analytics



News & Media

Add fund to favorites
Save this fund for later to form your own custom list of funds
This summary is composed by our algorithm based on the analysis of the deals. If you think that some of this information is not accurate, please let us know about it and provide any supporting evidences if possible. Such cases will be analyzed by our ML-algorithm and implemented in our database, which will improve this summary.
Total investments 45
Average round size
The average size of a deal this fund participated in
Portfolio companies 38
Rounds per year 9.00
Lead investments 12
Follow on index
How often the fund supports its portfolio startups at next rounds
Exits 14
Key employees 3
Stages of investment
Early Stage Venture
Late Stage Venture

Areas of investment

  • Biotechnology
  • Health Care
  • Pharmaceutical
  • Medical
  • Therapeutics

Considering the real fund results, this VC is 38 percentage points more often commits exit comparing to other organizations. The fund is generally included in 7-12 deals every year. The usual things for fund are deals in the range of 50 - 100 millions dollars. The high activity for fund was in 2018. The higher amount of exits for fund were in 2019. This 6 Dimensions Capital works on 16 percentage points less the average amount of lead investments comparing to the other organizations.

The standard case for the fund is to invest in rounds with 6-7 partakers. Despite the 6 Dimensions Capital, startups are often financed by ARCH Venture Partners, WuXi Healthcare Ventures, Venrock. The meaningful sponsors for the fund in investment in the same round are ARCH Venture Partners, Hillhouse Capital Group, Boyu Capital. In the next rounds fund is usually obtained by Temasek Holdings, Yonghua Capital, Windham Venture Partners.

Besides, a startup requires to be at the age of 4-5 years to receive the investment from the fund. Among the various public portfolio startups of the fund, we may underline GRAIL, CStone Pharmaceuticals, Yiyao The fund has specific favorite in a number of founders of portfolio startups. In case when startup counts 4 or 5+ of the founder, the chance for it to get the investment is meager. Among the most successful fund investment fields, there are Pharmaceutical, Medical Device.

We also calculated 3 valuable employees in our database.

Read more

Related Funds

Funds investing in previous rounds
These funds often invest in the rounds preceeding the rounds of 6 Dimensions Capital:
Typical Co-investors
6 Dimensions Capital is more likely to invest in rounds together with the following funds:
Funds investing in following rounds
These funds have a tendency to invest in the following rounds after 6 Dimensions Capital:

Funds with similar focus

Funds from China
Funds with similar focus located in China:
Funds with the same geo focus
Funds with similar geography of portfolio companies:
Funds doing lead investments
Funds with similar focus acting as lead investors:

Notable deals

CompanyIndustryRound SizeDateInvestorsLocation

Ignis Therapeutics

$180M11 Nov 2021 Shanghai, Shanghai, China

Exo Therapeutics

Health Care
$78M05 Oct 2021 Cambridge, Massachusetts, United States

Engine Biosciences

Artificial Intelligence
Health Care
Machine Learning
$43M26 May 2021 San Francisco, California, United States

TScan Therapeutics

Health Care
$100M25 Jan 2021 Massachusetts, United States

Fog Pharmaceuticals

Health Care
$107M11 Jan 2021 Cambridge, Massachusetts, United States

Exo Therapeutics

Health Care
$25M16 Dec 2020 Cambridge, Massachusetts, United States


Health Diagnostics
$50M03 Dec 2020 Misgav Dov, HaMerkaz, Israel

Kira Pharmaceuticals

16 Nov 2020 Hong Kong Island, Hong Kong, China

Halda Therapeutics

$25M13 Nov 2020 Branford, Connecticut, United States
Engine Biosciences Announces $43 Million Series A Round to Decipher Genetic Codes for New Medicines Through Machine Learning and Next-Generation Combinatorial Genetics

– Engine Biosciences announced the successful completion of an oversubscribed $43m Series A funding round.
– Engine identifies errors in the complex genetic codes of diseases, fixing them with precise therapeutic solutions.
– This round was led by Polaris Partners and also included new investors Invus and one of the world’s premier institutional investors, based in Singapore.
– Existing investors also participated in the Series A, which included 6 Dimensions Capital, WuXi AppTec, DHVC, EDBI, Baidu Ventures, Vectr Ventures, Goodman Capital, WI Harper, and Nest.Bio.
– Amy Schulman, Managing Partner at Polaris Partners, has joined the Engine Biosciences Board of Directors.

FogPharma® Announces $107 Million Series C Financing to Advance Direct β-Catenin Antagonist and Universal Druggability™ Platform

– FogPharma announced the completion of a $107m Series C financing round.
– The round was led by venBio Partners with participation from new investors Cormorant Asset Management, Farallon Capital Management, Invus, funds and accounts advised by T. Rowe Price Associates, Inc.; HBM Healthcare Investments, Casdin Capital, and PagsGroup.
– Existing investors, including GV, 6 Dimensions Capital, Deerfield Management and Blue Pool Capital also participated in the oversubscribed round.
– FogPharma’s proprietary hyperstabilized α-helical peptides (Helicon™ peptides) are a new class of therapeutics that combine the targeting strength and specificity of antibodies with the broad tissue distribution, intracellular target engagement and oral dosing optionality of small molecules.


  • No reviews are submitted yet.
Do you want more?
We provide dozens of additional datapoints about this fund.
Sign up and get access to full fund profile and advanced analysis.
Full team
Industries heatmap
Stages heatmap
Georgaphy breakdown
Portfolio analysis
Performance indexes
Latest highlights
Unlock all data
Do you represent 6 Dimensions Capital?
Get access to manage this page
Get in touch
Found incorrect info? Let us know!

You can raise money with us faster

Get matched with relevant funds

Find decision makers data

Connect with investors by email

Remind me later
...and save more than 200 hours*
*-Our recommendation and outreach system saves up to 200 hours of founder time on fundraising for seed and series A+ startups
We use LinkedIn only to verify your account. We don't import or message your contacts, nor post on your behalf.
By creating an account, you agree to our Terms of Service and Privacy Policy.
Crunchbase icon

Content report

The following text will be sent to our editors: